Wellington Zhaotai Therapies Limited Report issue

For profit Phase 1
Founded: Wellington Australia (2017)

Organization Overview

First Clinical Trial
2019
NCT04049513
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Wellington Zhaotai Therapies Limited

Active Ingredients

Drugs in Phase 1 Trials (3)

1928t2z car-t cell (1 trial)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Mantle-Cell (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 3